One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response

[GlobeNewswire] – GAITHERSBURG, Md. — Novavax, Inc. today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years … more

View todays social media effects on NVAX

View the latest stocks trending across Twitter. Click to view dashboard

See who Novavax is hiring next, click here to view